AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7926076
Drug: Dydrogesterone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dydrogesterone (40 mg)
Trial: 2684174
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms of muroctasin for 6 days post-chemotherapy
Trial: 2684174
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms of muroctasin for 6 days post-chemotherapy
Trial: 786689
Drug: Practolol (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practolol (1600 mg/day)
Trial: 786689
Drug: Chlorthalidone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (100 mg 3 times weekly)
Trial: 31157556
Drug: Lactobacillus reuteri-containing
RxNorm normalized name: Lactobacillus reuteri-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri-containing lozenges (three lozenges per day for two weeks)
Trial: 31157556
Drug: Placebo lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenges (three lozenges per day for two weeks)
Trial: 28578646
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% with 100 mcg clonidine
Trial: 28578646
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% with 4 mg dexamethasone and 100 mcg clonidine
Trial: 28578646
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% with 4 mg dexamethasone
Trial: 19563186
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with oral administration of Flunarizine Hydrochloride vacuity capsules, thrice each week for 4 weeks.
Trial: 19563186
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Flunarizine Hydrochloride capsules combined with acupuncture at placebo-points, thrice each week for 4 weeks.
Trial: 16889569
Drug: TCC locked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCC locked with cefotaxime (10 mg/mL) and heparin (5000 U/mL)
Trial: 16889569
Drug: TCC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCC with heparin (5000 U/mL) alone
Trial: 9425400
Drug: GHRH infusion
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH infusion
Trial: 9425400
Drug: GHRH +
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH + GHRP-2 infusion
Trial: 8505663
Drug: Albendazole (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (600 mg single dose)
Trial: 18462303
Drug: Compeed cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compeed cold sore patch (CSP)
Trial: 18462303
Drug: Acyclovir cream
RxNorm normalized name: Acyclovir Cream
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir cream 5%
Trial: 9252517
Drug: loxiglumide (CCK-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loxiglumide (CCK-A antagonist)
Trial: 1492262
Drug: Ampicillin/sulbactam (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin/sulbactam (1.0 g/0.5 g) with probenecid (1 g)
Trial: 1492262
Drug: Ceftriaxone (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (0.25 g)
Trial: 29380728
Drug: Everolimus (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (1.5 mg twice daily)
Trial: 20953593
Drug: Teriparatide 20
RxNorm normalized name: TERIPARATIDE 200UNT/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide 20 μg (4.86 μmol)
Trial: 17114888
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test (OGTT) in patients with active acromegaly (AA)
Trial: 17114888
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test (OGTT) in group A controls
Trial: 17114888
Drug: Insulin tolerance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin tolerance test (ITT) in patients with growth hormone deficiency (GHD)
Trial: 17114888
Drug: Insulin tolerance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin tolerance test (ITT) in group B controls
Trial: 12412171
Drug: Chemotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen (Arm Y: every 4 weeks; Arm Z: every 3 weeks) consisting of epirubicin (240 mg/m(2)), bleomycin (60 mg/m(2)), vinblastine (20 mg/m(2)), vincristine (4 mg/m(2)), cyclophosphamide (4000 mg/m(2)), etoposide (900 mg/m(2)), methotrexate (180 mg/m(2)), methylprednisolone (1500 mg/m(2)) over 12 weeks followed by extended-field lymph node irradiation (involved areas, 40 grays [Gy]; noninvolved areas, 30 Gy).
Trial: 12412171
Drug: Chemotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen (Arm Z: every 3 weeks) consisting of epirubicin (240 mg/m(2)), bleomycin (60 mg/m(2)), vinblastine (20 mg/m(2)), vincristine (4 mg/m(2)), cyclophosphamide (4000 mg/m(2)), etoposide (900 mg/m(2)), methotrexate (180 mg/m(2)), methylprednisolone (1500 mg/m(2)) over 12 weeks followed by extended-field lymph node irradiation (involved areas, 40 grays [Gy]; noninvolved areas, 30 Gy).
Trial: 10807190
Drug: Combination tablet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet regimen (lamivudine 150 mg/zidovudine 300 mg twice daily plus a protease inhibitor)
Trial: 10807190
Drug: Conventional regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional regimen (150 mg lamivudine twice daily, 600 mg zidovudine daily, and a protease inhibitor)
Trial: 10807190
Drug: Combination tablet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet regimen
Trial: 8794812
Drug: Estrogen supplementation
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen supplementation (estradiol valerate, 2 mg daily, n = 6)
Trial: 6465489
Drug: Oral controlled-release
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral controlled-release morphine 20 mg
Trial: 24559810
Drug: Ginger powder
RxNorm normalized name: Emergen-C Turmeric & Ginger Powder for Solution (Citrus-Ginger)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger powder supplementation (3 one-gram capsules daily for 8 weeks)
Trial: 24559810
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 one-gram microcrystalline-containing capsules daily for 8 weeks)
Trial: 17921390
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg Zn/d as a supplement
Trial: 16173138
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (12.5 mmol daily for 6 weeks)
Trial: 12549635
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (without Tamsulosin)
Trial: 10553163
Drug: IL‐3 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐3 (10 microg/kg/day, s.c., day 1‐5) followed by G‐CSF (5 microg/kg/day, day 6‐8)
Trial: 10553163
Drug: IL‐3+G‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐3+G‐CSF
Trial: 26474174
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus icotinib (125 mg thrice daily for 4-8 months)
Trial: 21263367
Drug: Intermittent propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent propofol sedation (bolus of 2-4 mg/kg, followed by repeat boluses of 0.5-2 mg/kg/dose as needed)
Trial: 21263367
Drug: Continuous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous propofol sedation (bolus of 2-4 mg/kg, followed by continuous infusion of 100 μg/kg/min with 1-mg/kg/dose boluses)
Trial: 19100061
Drug: Coxsackievirus binding
RxNorm normalized name: coxsackievirus A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coxsackievirus binding domain (exon 4) of Adenovirus receptor (CAR) in DCM patients
Trial: 19100061
Drug: Coxsackievirus binding
RxNorm normalized name: coxsackievirus A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coxsackievirus binding domain (exon 4) of Adenovirus receptor (CAR) in healthy adults
Trial: 12883406
Drug: Sufentanil effect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil effect site concentration of 0.5 ng/ml (group 1)
Trial: 12883406
Drug: Sufentanil effect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil effect site concentration of 1.25 ng/ml (group 4)
Trial: 12883406
Drug: Mean arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean arterial pressure, heart rate, time to tracheal extubation, awareness, satisfaction scores, morphine requirements
Trial: 2054278
Drug: Chlorpheniramine 4
RxNorm normalized name: chlorpheniramine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine 4 mg with paracetamol 650 mg
Trial: 29384326
Drug: 75‐g 2‐h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75‐g 2‐h oral glucose tolerance test (OGTT)
Trial: 25197908
Drug: Real ear
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real ear acupressure (EAP) treatment
Trial: 25197908
Drug: Sham ear
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ear acupressure (EAP) treatment
Trial: 21187618
Drug: 5.25% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.25% sodium hypochlorite solution
Trial: 12208796
Drug: Amoxicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (500 mg twice daily), metronidazole (400 mg twice daily), and omeprazole (20 mg twice daily)
Trial: 12208796
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg once daily), metronidazole (400 mg twice daily), and omeprazole (20 mg twice daily)
Trial: 12208796
Drug: Antibiotics (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (both regimens)
Trial: 1823064
Drug: Ranitidine injection
RxNorm normalized name: ranitidine Injection
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine injection (5 minutes before pentagastrin)
Trial: 1823064
Drug: Ranitidine injection
RxNorm normalized name: ranitidine Injection
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine injection (1 hour before pentagastrin)
Trial: 1823064
Drug: Short-term oral
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term oral intake of ranitidine
Trial: 30118784
Drug: Nutrition and
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition and Culinary in the Kitchen (NCK) Program, 6-week duration, 3 hours weekly, including hands-on cooking classes and a food market visit
Trial: 26952222
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine infusion at a rate of 1.5mg/kg/min
Trial: 26952222
Drug: IV esmolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV esmolol infusion at a rate of 1mg/kg/min
Trial: 20388562
Drug: Partial rectal
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial rectal wall advancement flap (Group I)
Trial: 18821872
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for alcohol dependence (details on specific medications or behavioral interventions not provided)
Trial: 18821872
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for alcohol dependence
Trial: 12795130
Drug: Continuous extradural
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous extradural infusion of bupivacaine
Trial: 12795130
Drug: Continuous extradural
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous extradural infusion of morphine
Trial: 6349743
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of emepronium bromide and flavoxate hydrochloride
Trial: 30419226
Drug: Ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600 mg, 3 times daily, started 4 hours before the ascent)
Trial: 30419226
Drug: Acetazolamide (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (125 mg, twice daily, started the night before the ascent)
Trial: 28462933
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behaviour therapy (group‐CBT) added to standard spinal cord injury inpatient rehabilitation (SR)
Trial: 25613747
Drug: Intravenous GIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GIP (4 pmol/kg/min)
Trial: 22447467
Drug: Candesartan, 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan, 12 mg monotherapy (group A)
Trial: 22447467
Drug: Hydrochlorothiazide (HCTZ),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ), 6.25 mg in combination with candesartan, 8 mg (group B)
Trial: 16998171
Drug: Active nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active nicotine patches (6-week reducing dose regimen)
Trial: 8466240
Drug: Protein restricted
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein restricted diet (0.8‐1.1 g/kg/day)
Trial: 25667123
Drug: Achillea millefolium
RxNorm normalized name: ACHILLEA MILLEFOLIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Achillea millefolium distillate solution (15 mL gargled 4 times a day for 14 days)
Trial: 25667123
Drug: Routine solution
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine solution (15 mL gargled 4 times a day for 14 days)
Trial: 16873950
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg coenzyme Q(10) soft oil capsules
Trial: 16873950
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg coenzyme Q(10) soft oil capsules
Trial: 16873950
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg crystalline Q(10) powder capsules
Trial: 23803687
Drug: Individual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual treatment (TBI SOLO)
Trial: 9354315
Drug: Frusemide +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide + Meloxicam (15 mg)
Trial: 3006414
Drug: Naloxone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (8 mg bolus in 20 ml normal saline)
Trial: 24946562
Drug: Compound Wuzhigan
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Wuzhigan capsules (2 capsules one time, three times a day for 3 days)
Trial: 24946562
Drug: Compound Wuzhigan
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Wuzhigan tablets (4 tablets one time, three times a day for 3 days)
Trial: 29943163
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg for 8 weeks
Trial: 22001942
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg for 4 weeks
Trial: 9814473
Drug: Human CG
RxNorm normalized name: CG-200745
DrugBank: CG-200745 (DB12259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human CG (10 U/mL)
Trial: 9814473
Drug: Interleukin (IL)-1
RxNorm normalized name: M-1095 (anti-interleukin (il)-17a/f single-domain antibody)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin (IL)-1 (10 ng/mL)
Trial: 9814473
Drug: Interleukin (IL)-4
RxNorm normalized name: interleukin-4
DrugBank: Binetrakin (DB12182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin (IL)-4 (10 ng/mL)
Trial: 9814473
Drug: Interleukin (IL)-10
RxNorm normalized name: interleukin-10
DrugBank: Interleukin-10 (DB12880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin (IL)-10 (10 ng/mL)
Trial: 2468927
Drug: Cicloprolol (0.025,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicloprolol (0.025, 0.025, 0.05, and 0.1 mg/kg)
Trial: 7095
Drug: Ketamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (2 mg/kg body weight, supplemented if necessary by 1 mg/kg) + Flunitrazepam (2 mg)
Trial: 7095
Drug: Ketamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (2 mg/kg body weight, supplemented if necessary by 1 mg/kg)
Trial: 31456003
Drug: Low-dose radiotherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiotherapy (RT) with single doses of 0.5Gy (total dose 3.0-5.0Gy)
Trial: 31456003
Drug: Low-dose radiotherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiotherapy (RT)
Trial: 25868059
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (220 mg zinc sulfate containing 50 mg zinc)
Trial: 22509642
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate (5 doses of 2.5 ml each, one dose per week)
Trial: 22509642
Drug: Methylprednisolone (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (single 2 ml dose)
Trial: 19874153
Drug: High-dose naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose naltrexone (100 mg/d)
Trial: 19874153
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) without Contingency Management (CM)
Trial: 15365066
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m2) plus cyclophosphamide (600 mg/m2) every 3 weeks for four cycles
Trial: 9423999
Drug: 22.5 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22.5 Gy in five daily fractions
Trial: 2958947
Drug: Aqueous procaine
RxNorm normalized name: Aqueous procaine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous procaine penicillin G (4.8 X 10(6) units im plus 1.0 g of oral probenicid)
Trial: 2958947
Drug: Oral ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ampicillin (3.5 g plus 1.0 g of oral probenicid)
Trial: 6240786
Drug: Spectinomycin (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectinomycin (2.0 g im)
Trial: 2958947
Drug: Oral rosoxacin
RxNorm normalized name: rosoxacin
DrugBank: Rosoxacin (DB00817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rosoxacin (300 mg)
Trial: 27260149
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine 2 μg/kg (Group I)
Trial: 27260149
Drug: Intranasal clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal clonidine 3 μg/kg (Group II)
Trial: 27260149
Drug: Intranasal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal saline 0.5 ml (Group III)
Trial: 19912160
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose Infusion
Trial: 16409700
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine treatment, no counselling)
Trial: 11151875
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg oral erythromycin
Trial: 1334539
Drug: cisplatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisplatin (80 mg/m2, day 1)/etoposide (100 mg/m2, days 1, 3, 5) (PE)
Trial: 1334539
Drug: cisplatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisplatin (80 mg/m2, day 1)/etoposide (100 mg/m2, days 1, 3, 5)/ifosfamide (2 g/m2, days 1, 2, 3) (PEI)
Trial: 6466532
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (lower dose range of glycopyrrolate and atropine)
Trial: 21696081
Drug: 0.5% isobaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% isobaric racemic bupivacaine 3 mL
Trial: 21696081
Drug: 0.5% isobaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% isobaric levobupivacaine 3 mL
Trial: 18713312
Drug: Acid infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acid infusion (HCl 0.15 mol L(‐1))